RvD1和LXA对心脏电压关卡通道的抑制作用
Alicia De la Cruz1, Carlotta Ronchi2, Chiara Bartolucci3
1Instituto de Investigaciones Biomédicas Sols-Morreale CSIC-UAM, Madrid, Spain; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
概括
像RvD1和LXA4这样的专门的亲解决媒介影响心脏离子通道. RvD1显著抑制了关键的电流,可能会逆转心房的重塑.
科学领域:
- 心血管生理学心血管生理学
- 分子药理学分子药理学
- 电子生理学 电子生理学
背景情况:
- 专门的亲溶解脂质调解剂 (SPMs) 缓解炎症,并且可以在心血管疾病中改变.
- 在动物模型中,RvD1和LXA4是已知的防止心房动 (AF) 重塑和心脏缩的SPM.
- 对于RvD1和LXA4对心脏电压关闭 (VG) 离子通道的电生理学影响仍然基本未知.
研究的目的:
- 研究RvD1和LXA4对心脏VG通道的急性电生理影响.
- 使用in silico模拟来评估RvD1和LXA4对心房和心室动作潜力 (AP) 的影响.
主要方法:
- 在异质系统和几内亚猪心肌细胞中的补丁电生理学.
- 评估多个VG电流,包括IKs,IKur,Ito,IKr和IK1.
- 在模型中预测AP变化.
主要成果:
- 在两种细胞类型中,RvD1显著降低了IKs电流,并显示出强大的IKr抑制.
- 在调节电流方面,RvD1比LXA4更强大.
- 在模拟中预测RvD1延长了心房和心室肌细胞的再极化.
结论:
- 在相关度下,RvD1和LXA4对心脏通道产生直接的电生理作用.
- RvD1对电流的强烈抑制表明它在逆转AF诱导的电力改造方面发挥了作用.
- 需要进一步的研究来证实RvD1对心室重塑的影响.
相关概念视频
Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...


